The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induced cytidine deaminase (AID) and its role in clinical outcome in 61 adult BCR-ABL1-positive ALL patients. AID expression was detected in 36 patients (59%); it correlated with the BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors. Different AID splice variants were identified: full-length isoform; AIDDeltaE4a, with a 30-bp deletion of exon 4; AIDDeltaE4, with the exon 4 deletion; AIDins3, with the retention of intron 3; AIDDeltaE3-E4 isoform without deaminase activity. AID-FL predominantly showed cytoplasmic localization, as did the AID-DeltaE4a and AID-DeltaE3E4 variants, whereas the C-terminal-truncated AID-DeltaE4 showed a slightly increased nuclear localization pattern. AID expression correlated with a higher number of copy number alterations identified in genome-wide analysis using a single-nucleotide polymorphism array. However, the expression of AID at diagnosis was not associated with a worse prognosis. In conclusion, BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that may act as mutators outside the immunoglobulin (Ig) gene loci in promoting genetic instability.

Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients / Iacobucci I; Lonetti A; Messa F; Ferrari A; Cilloni D; Soverini S; Paoloni F; Arruga F; Ottaviani E; Chiaretti S; Messina M; Vignetti M; Papayannidis C; Vitale A; Pane F; Piccaluga PP; Paolini S; Berton G; Baruzzi A; Saglio G; Baccarani M; Foà R; Martinelli G.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 24:1(2010), pp. 66-73. [10.1038/leu.2009.197]

Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.

IACOBUCCI, ILARIA;LONETTI, ANNALISA;FERRARI, ANNA;SOVERINI, SIMONA;OTTAVIANI, EMANUELA;PAPAYANNIDIS, CRISTINA;PICCALUGA, PIER PAOLO;PAOLINI, STEFANIA;BACCARANI, MICHELE;MARTINELLI, GIOVANNI
2010

Abstract

The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induced cytidine deaminase (AID) and its role in clinical outcome in 61 adult BCR-ABL1-positive ALL patients. AID expression was detected in 36 patients (59%); it correlated with the BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors. Different AID splice variants were identified: full-length isoform; AIDDeltaE4a, with a 30-bp deletion of exon 4; AIDDeltaE4, with the exon 4 deletion; AIDins3, with the retention of intron 3; AIDDeltaE3-E4 isoform without deaminase activity. AID-FL predominantly showed cytoplasmic localization, as did the AID-DeltaE4a and AID-DeltaE3E4 variants, whereas the C-terminal-truncated AID-DeltaE4 showed a slightly increased nuclear localization pattern. AID expression correlated with a higher number of copy number alterations identified in genome-wide analysis using a single-nucleotide polymorphism array. However, the expression of AID at diagnosis was not associated with a worse prognosis. In conclusion, BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that may act as mutators outside the immunoglobulin (Ig) gene loci in promoting genetic instability.
2010
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients / Iacobucci I; Lonetti A; Messa F; Ferrari A; Cilloni D; Soverini S; Paoloni F; Arruga F; Ottaviani E; Chiaretti S; Messina M; Vignetti M; Papayannidis C; Vitale A; Pane F; Piccaluga PP; Paolini S; Berton G; Baruzzi A; Saglio G; Baccarani M; Foà R; Martinelli G.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - 24:1(2010), pp. 66-73. [10.1038/leu.2009.197]
Iacobucci I; Lonetti A; Messa F; Ferrari A; Cilloni D; Soverini S; Paoloni F; Arruga F; Ottaviani E; Chiaretti S; Messina M; Vignetti M; Papayannidis C; Vitale A; Pane F; Piccaluga PP; Paolini S; Berton G; Baruzzi A; Saglio G; Baccarani M; Foà R; Martinelli G.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/83051
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 20
social impact